Rankings / Longevity — Pharma (Off-Label)

Rapamycin (sirolimus)

Longevity · mTOR inhibitor

Tier C

mtor-inhibitionautophagyprescription
5 / 10
Tier C
Ev 4.5 Bn 6.5 Sf 5

Bottom line

Read Off Label grades Rapamycin (sirolimus) as C (5.0/10) based on moderate-weak evidence, med-high benefit magnitude, and a med-risk safety profile.

ITP: single most reproducible life-extending compound in mammals.

Typical use: 5-10 mg PO weekly (off-label longevity dosing); much higher for transplant — Rx.

What this is

ITP: single most reproducible life-extending compound in mammals. PEARL trial (Moel et al, Aging April 2025; n=114, 48 weeks, 5 or 10 mg weekly): MISSED primary endpoint of visceral adiposity reduction (η²=0.001, p=0.94) and most biomarkers unchanged. Secondary signals: lean tissue mass and self-reported pain improved in women on 10 mg; emotional well-being and general health improved at 5 mg. Adverse events similar to placebo — confirming safety at these doses. Most discussed longevity drug but human efficacy data remains underwhelming.

Mechanism

Binds FKBP12; inhibits mTORC1 — the central nutrient-sensing kinase complex; induces autophagy; reduces protein synthesis; intermittent dosing may spare mTORC2

Dose & route

5-10 mg PO weekly (off-label longevity dosing); much higher for transplant

Common questions

Does Rapamycin (sirolimus) work?
Read Off Label rates the evidence for Rapamycin (sirolimus) as Moderate-Weak and the benefit magnitude as med-high, producing an overall grade of C (5.0/10). ITP: single most reproducible life-extending compound in mammals.
Is Rapamycin (sirolimus) safe?
Rapamycin (sirolimus) has a med risk profile in published human data. Legal status: Rx (off-label for longevity). This is not medical advice — see the disclaimer.
What is the typical dose for Rapamycin (sirolimus)?
5-10 mg PO weekly (off-label longevity dosing); much higher for transplant
How does Rapamycin (sirolimus) work?
Binds FKBP12; inhibits mTORC1 — the central nutrient-sensing kinase complex; induces autophagy; reduces protein synthesis; intermittent dosing may spare mTORC2

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.